Inventiva Share Price Today

Canaccord Genuity raises Inventiva price target to $21, maintains Buy

Canaccord Genuity raised Inventiva's price target to $21 from $20, maintaining Buy rating. H1FY26 net loss narrowed 61% YoY to €69.5 million, driven by financial swings. EPS of $(0.29) missed consensus estimates of $(0.20) by 45%. Cash runway extended through Q2 2027, potentially Q1 2028 with further financing.

Inventiva completes NATiV3 trial visits; topline data due Q4 2026

Last patient in NATiV3 Phase 3 trial completed final 72-week visit. Trial enrolled 1,009 patients in main cohort and 410 in exploratory cohort. Topline results for lanifibranor expected in Q4 2026. Potential US launch targeted for 2028 if results are favorable.

Inventiva Q2 Results: Cash position rises to €166.1M after funding

Inventiva’s H1 2026 preliminary results show a strengthened balance sheet with €166.1 million in cash and €67.8 million in short-term deposits, bolstered by recent equity and debt financings. Operating cash burn decreased to €48.7 million despite higher R&D spend of €50.1 million for its MASH therapy trial. The company projects its current funds will last until mid-2027, with potential extension to early 2028 if additional warrant exercises and debt tranches materialize.

Cantor Fitzgerald initiates coverage on Inventiva with Overweight rating

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Inventiva with an Overweight rating, signaling a positive outlook for the NASDAQ-listed biotech company.

Inventiva completes EIB warrant restructuring to simplify capital structure

Inventiva has completed the restructuring of its EIB warrants by issuing 15.7 million new warrants and cancelling legacy instruments. The new warrants, exercisable from August 30, 2026, to January 4, 2036, remove anti-dilution protections and simplify the capital structure. The EIB now holds 3.6% of the company on a fully-diluted basis.

Inventiva Combined Shareholders' Meeting: 39 of 40 Resolutions Adopted at June 30, 2026 General Meeting

Inventiva held its Combined Shareholders' General Meeting on June 30, 2026, in Paris, achieving a quorum of 71,874% with 440 shareholders representing 169 824 140 shares. Of 40 resolutions submitted, 39 were adopted, including all ordinary resolutions and 18 of 19 extraordinary resolutions. The sole rejected resolution — the 31st — which would have authorised share capital increases for a company savings plan, received only 45,94% of votes in favour against 54,06% opposed, in line with the Board of Directors' prior negative recommendation.